Study on the Safety and Effectiveness of AZD5492, a T Cell-Engaging Antibody for Treating Relapsed or Refractory B-Cell Cancers

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of a CD20-positive B-cell cancer, such as:
  • Large B-cell lymphoma
  • Follicular lymphoma
  • Mantle cell lymphoma
  • Chronic lymphocytic leukemia
  • Small lymphocytic lymphoma
• The cancer must have returned or not responded after at least two previous treatments.
• Be in relatively good health with an ECOG performance status of 2 or lower, meaning fully active or able to do light work.

Note: Additional criteria may apply.

Exclusion Criteria

• Have active cancer involvement in the brain or other central nervous system issues.
• Have certain types of aggressive lymphomas, such as post-transplant lymphoproliferative disease, Richter's transformation, Burkitt's lymphoma, or Burkitt-like lymphoma.
• Have had a stem cell transplant within the last 90 to 180 days, depending on the type, or cell therapy within the last 90 days.
• Have a history of severe side effects from previous cancer treatments, such as high-grade cytokine release syndrome (CRS) or neurotoxicity (ICANS).
• Have active and uncontrolled infections.
• Have unresolved side effects from previous cancer treatments that are moderate or severe, with some exceptions.

Note: Additional criteria may apply.